Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart.
Saved in:
| Title: | Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart. |
|---|---|
| Authors: | Van de Walle I; argenx, Ghent, Belgium. IVandeWalle@argenx.com., Bracke L; argenx, Ghent, Belgium., Olesen HG; Department of Molecular Biology and Genetics - Protein Science, Universitetsbyen 81, 8000, Aarhus C, Denmark., van Bragt T; Curare Consulting BV, Liempde, The Netherlands., Cadour S; argenx, Ghent, Belgium., De Decker P; argenx, Ghent, Belgium., Ciurlia G; argenx, Ghent, Belgium., Pannecoucke E; argenx, Ghent, Belgium., Persson EK; argenx, Ghent, Belgium., Van de Steen O; argenx, Ghent, Belgium., Leng X; argenx, Ghent, Belgium., Andersen GR; Department of Molecular Biology and Genetics - Protein Science, Universitetsbyen 81, 8000, Aarhus C, Denmark., Gandini D; argenx, Ghent, Belgium., Hack CE; argenx, Ghent, Belgium. |
| Source: | Nature communications [Nat Commun] 2025 Aug 16; Vol. 16 (1), pp. 7639. Date of Electronic Publication: 2025 Aug 16. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-62925-1 |
